These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 2586763

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F, Vacca L, Ruggieri S, Olanow CW.
    Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989 Sep; 19(6):415-21. PubMed ID: 2690730
    [Abstract] [Full Text] [Related]

  • 29. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
    Devos D, French DUODOPA Study Group.
    Mov Disord; 2009 May 15; 24(7):993-1000. PubMed ID: 19253412
    [Abstract] [Full Text] [Related]

  • 30. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D, Friedman A.
    Mov Disord; 2007 May 15; 22(7):1033-6. PubMed ID: 17370308
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
    Alvarez L, Macias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, Juncos JL, Maragoto C, Guridi J, Litvan I, Tolosa ES, Koller W, Vitek J, DeLong MR, Obeso JA.
    Brain; 2005 Mar 15; 128(Pt 3):570-83. PubMed ID: 15689366
    [Abstract] [Full Text] [Related]

  • 33. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
    Antonini A, Tolosa E.
    Expert Rev Neurother; 2009 Jun 15; 9(6):859-67. PubMed ID: 19496689
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct 15; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 37. L-dopa treatment and Parkinson's disease.
    Lees AJ.
    Q J Med; 1986 Jun 15; 59(230):535-47. PubMed ID: 3529159
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.